Startseite The association between plasma carnitines and duration of diabetic ketoacidosis treatment in children with type 1 diabetes
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

The association between plasma carnitines and duration of diabetic ketoacidosis treatment in children with type 1 diabetes

  • Deniz Okdemir , Aysel Acikgozoglu , Abdurrahman Akgun und Ihsan Esen ORCID logo EMAIL logo
Veröffentlicht/Copyright: 6. Oktober 2022

Abstract

Objectives

The aim of this study is to determine the plasma free carnitine and acyl-carnitine levels at the time of diabetic ketoacidosis (DKA) diagnosis, and at the end of DKA treatment and to investigate their association with the duration of DKA treatment in children with DKA.

Methods

A total of 40 children with DKA who were treated consecutively in a tertiary health center for DKA were included in the study. The median age of the children was 11.3 years (1.1–17.5) and 25 of them (62.5%) were girls. In addition to routine blood tests, plasma free carnitine and acyl-carnitine levels were measured just before the start of intravenous insulin therapy and at the time of discontinuation of intravenous insulin therapy when DKA therapy was completed.

Results

There was no difference in plasma free carnitine and acyl-carnitine levels before and after DKA treatment (p=0.776 and p=0.743 respectively). However, while the frequency of low plasma free carnitine was 30% at the beginning of the treatment, it was observed that this frequency was 20% at the end of the DKA treatment. There was no correlation between duration of DKA treatment and plasma free carnitine or acyl-carnitine levels at admission (p=0.497, r=−0.111 and p=0.474, r=0.116 respectively).

Conclusions

There is no a relationship between duration of DKA treatment and plasma free carnitine or acyl-carnitine level at admission in children with DKA.


Corresponding author: Prof. Ihsan Esen, Department of Pediatric Endocrinology, Chair of Pediatrics, Medical School of Firat University, Elazig, Turkey, Phone: +90 424 2333555 – 2365, E-mail:

  1. Research funding: None declared.

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Authors state no conflict of interest.

  4. Informed consent: Informed consent was obtained from the legal guardians of all individuals included in this study.

  5. Ethical approval: Ethical approval for the study was obtained from the local Ethics Committee.

References

1. Wolfsdorf, JI, Glaser, N, Agus, M, Fritsch, M, Hanas, R, Rewers, A, et al.. ISPAD clinical practice consensus guidelines 2018: diabetic ketoacidosis and the hyperglycemic hyperosmolar state. Pediatr Diabetes 2018;19:155–77. https://doi.org/10.1111/pedi.12701.Suche in Google Scholar PubMed

2. Hoffman, WH, Siedlak, SL, Wang, Y, Castellani, RJ, Smith, MA. Oxidative damage is present in the fatal brain edema of diabetic ketoacidosis. Brain Res 2011;1369:194–202. https://doi.org/10.1016/j.brainres.2010.10.085.Suche in Google Scholar PubMed PubMed Central

3. Adeva-Andany, MM, Calvo-Castro, I, Fernandez-Fernandez, C, Donapetry-Garcia, C, Pedre-Pineiro, AM. Significance of l-carnitine for human health. IUBMB Life 2017;69:578–94. https://doi.org/10.1002/iub.1646.Suche in Google Scholar PubMed

4. Genuth, SM, Hoppel, CL. Plasma and urine carnitine in diabetic ketosis. Diabetes 1979;28:1083–7. https://doi.org/10.2337/diab.28.12.1083.Suche in Google Scholar PubMed

5. Soltesz, G, Melegh, B, Sandor, A. The relationship between carnitine and ketone body levels in diabetic children. Acta Paediatr Scand 1983;72:511–5. https://doi.org/10.1111/j.1651-2227.1983.tb09762.x.Suche in Google Scholar PubMed

6. Jahoor, F, Hsu, JW, Mehta, PB, Keene, KR, Gaba, R, Mulukutla, SN, et al.. Metabolomics profiling of patients with A-beta+ ketosis-prone diabetes during diabetic ketoacidosis. Diabetes 2021;70:1898–909. https://doi.org/10.2337/db21-0066.Suche in Google Scholar PubMed PubMed Central

7. Hoffman, WH, Whelan, SA, Lee, N. Tryptophan, kynurenine pathway, and diabetic ketoacidosis in type 1 diabetes. PLoS One 2021;16:e0254116. https://doi.org/10.1371/journal.pone.0254116.Suche in Google Scholar PubMed PubMed Central

8. Schmidt-Sommerfeld, E, Werner, D, Penn, D. Carnitine plasma concentrations in 353 metabolically healthy children. Eur J Pediatr 1988;147:356–60. https://doi.org/10.1007/bf00496410.Suche in Google Scholar PubMed

9. Cederblad, G, Hermansson, G, Ludvigsson, J. Plasma and urine carnitine in children with diabetes mellitus. Clin Chim Acta 1982;125:207–17. https://doi.org/10.1016/0009-8981(82)90197-8.Suche in Google Scholar PubMed

10. Winter, SC, Simon, M, Zorn, EM, Szabo-Aczel, S, Vance, WH, O’Hara, T, et al.. Relative carnitine insufficiency in children with type I diabetes mellitus. Am J Dis Child 1989;143:1337–9. https://doi.org/10.1001/archpedi.1989.02150230095030.Suche in Google Scholar PubMed

11. Mamoulakis, D, Galanakis, E, Dionyssopoulou, E, Evangeliou, A, Sbyrakis, S. Carnitine deficiency in children and adolescents with type 1 diabetes. J Diabet Complicat 2004;18:271–4. https://doi.org/10.1016/s1056-8727(03)00091-6.Suche in Google Scholar

12. Malone, JI, Schocken, DD, Morrison, AD, Gilbert-Barness, E. Diabetic cardiomyopathy and carnitine deficiency. J Diabet Complicat 1999;13:86–90. https://doi.org/10.1016/s1056-8727(99)00039-2.Suche in Google Scholar PubMed

13. Negro, P, Gossetti, F, Pinta, ML, Mariani, P, Carboni, M. The effect of L-carnitine, administered through intravenous infusion of glucose, on both glucose and insulin levels in healthy subjects. Drugs Exp Clin Res 1994;20:257–62.Suche in Google Scholar

14. Mingrone, G. Carnitine in type 2 diabetes. Ann N Y Acad Sci 2004;1033:99–107. https://doi.org/10.1196/annals.1320.009.Suche in Google Scholar PubMed

Received: 2022-08-26
Accepted: 2022-09-19
Published Online: 2022-10-06
Published in Print: 2022-12-16

© 2022 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Review Article
  3. The efficacy and safety of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 agonists in pediatric patients with type 2 diabetes: a systematic review
  4. Original Articles
  5. Triple burden of malnutrition and role of anaemia in the development of complications associated with type 1 diabetes in Indian children and youth
  6. Effect of obesity and excessive body fat on glycaemic control in paediatric type 1 diabetes
  7. Role of pan immune inflammatory value in the evaluation of hepatosteatosis in children and adolescents with obesity
  8. Secular trends of birth weight and its associations with obesity and hypertension among Southern Chinese children and adolescents
  9. Insights into the implication of obesity in hypogonadism among adolescent boys
  10. The association between plasma carnitines and duration of diabetic ketoacidosis treatment in children with type 1 diabetes
  11. Cathelicidin as a marker for subclinical cardiac changes and microvascular complications in children and adolescents with type 1 diabetes
  12. Developing a risk assessment tool for identifying individuals at high risk for developing insulin resistance in European adolescents: the HELENA-IR score
  13. Hemoglobin A1C can differentiate subjects with GCK mutations among patients suspected to have MODY
  14. Perceptions and use of complementary and alternative medicine in patients with precocious puberty
  15. Case Reports
  16. Infection with SARS-CoV-2 may alter the half-life of desmopressin (DDAVP) in patients with central diabetes insipidus
  17. Heterozygous CDC73 mutation causing hyperparathyroidism in children and adolescents: a report of 2 cases
  18. Wolfram syndrome in a young woman with associated hypergonadotropic hypogonadism – A case report
  19. Continuous glucose monitoring in an infant with panhypopituitarism having hypoglycemia on growth hormone therapy
  20. Severe consumptive hypothyroidism in hepatic hemangioendothelioma
  21. Efficacy of aromatase inhibitor therapy in a case with large cell calcifying Sertoli cell tumour-associated prepubertal gynaecomastia
Heruntergeladen am 13.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/jpem-2022-0431/html
Button zum nach oben scrollen